Home
Paraneoplastic Neurological Syndromes (PNS) research group

Publications

List of publications

Photo:
www.colourbox.no

Main content

Recent Impactful Publications (2019-Present):

1) Nes MS, Haugen M, Haugland HK, Gilhus NE, Vedeler CA. Case report: Seropositive myasthenia gravis complicated by limbic encephalitis positive for antibodies to AMPAR and Lgi1. Front Neurol. 2023 Oct 12;14:1237140. doi: 10.3389/fneur.2023.1237140. 

2) Erikstad KI, Herdlevaer I, Peter E, Haugen M, Totland C, Vedeler C. A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration. Eur J Neurol. 2023 Jun;30(6):1727-1733. doi: 10.1111/ene.15786. 

3) Uggerud IM, Kråkenes T, Hirai H, Vedeler CA, Schubert M. Development and Optimization of a Multilayer Rat Purkinje Neuron Culture. Cerebellum. 2023 Jan 10. doi: 10.1007/s12311-022-01510-4. 

4) Greenlee JE, Carlson NG, Abbatemarco JR, Herdlevær I, Clardy SL, Vedeler CA. Editorial: Autoimmunity and the Brain: Paraneoplastic Neurological Injury and Beyond. Front Neurol. 2022 May 12;13:900130. doi: 10.3389/fneur.2022.900130. 

5) Greenlee JE, Carlson NG, Abbatemarco JR, Herdlevær I, Clardy SL, Vedeler CA. Paraneoplastic and Other Autoimmune Encephalitides: Antineuronal Antibodies, T Lymphocytes, and Questions of Pathogenesis. Front Neurol. 2022 Jan 17;12:744653. doi: 10.3389/fneur.2021.744653. 

6) Raspotnig M, Kråkenes T, Herdlevær I, Haugen M, Vedeler C. Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue. J Neuroimmunol. 2022 Jan 15;362:577766. doi: 10.1016/j.jneuroim.2021.577766. 

7) Totland C, Haugen M, Vedeler C. CRMP5 Antibodies-Diagnostic Challenges. Front Neurol. 2021 Sep 22;12:729075. doi: 10.3389/fneur.2021.729075. 

8) Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, McKeon A, Prüss H, Psimaras D, Thomas L, Titulaer MJ, Vedeler CA, Verschuuren JJ, Dalmau J, Honnorat J. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021 May 18;8(4):e1014. doi: 10.1212/NXI.0000000000001014. 

9) Herdlevær I, Haugen M, Mazengia K, Totland C, Vedeler C. Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 2;8(2):e963. doi: 10.1212/NXI.0000000000000963. 

10) Varhaug KN, Hikmat O, Nakkestad HL, Vedeler CA, Bindoff LA. Serum biomarkers in primary mitochondrial disorders. Brain Commun. 2021 Jan 4;3(1):fcaa222. doi: 10.1093/braincomms/fcaa222. 

11) Herdlevaer I, Kråkenes T, Schubert M, Vedeler CA. Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration. Ann Clin Transl Neurol. 2020 Nov;7(11):2231-2242. doi: 10.1002/acn3.51212. 

12) Kråkenes T, Herdlevaer I, Raspotnig M, Haugen M, Schubert M, Vedeler CA. CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration. Ann Neurol. 2019 Aug;86(2):316-321. doi: 10.1002/ana.25511. Epub 2019 Jun 13. 

 

 

Classic Contributions:

  • Totland C, Kråkenes T, Mazengia K, Haugen M, Vedeler CA. Expression of the onconeural protein CDR1 in cerebellum and ovarian cancer. Oncotarget 2018 May 8;9(35):23975–23986. [doi: 10.18632/oncotarget.25252]
     
  • Panja D, Vedeler CA, Schubert M. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity. Neuropathol Appl Neurobiol. 2018 Apr 21. [doi: 10.1111/nan.12492]
     
  • Eichler TW, Totland C, Haugen M, Vedeler CA. CCDC104 Antibodies and Mitosis of Cancer Cells. Scand J Immunol. 2018 Feb;87(2):109-110. [doi: 10.1111/sji.12634]
     
  • Raspotnig M, Haugen M, Thorsteinsdottir M, Stefansson I, Salvesen HB, Storstein A, Vedeler CA. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies. Cancer Immunol Immunother. 2017 Nov;66(11):1463-1471. [doi: 10.1007/s00262-017-2041-8]
     
  • Storstein A, Raspotnig M, Vitaliani R, Giometto B, Graus F, Grisold W, Honnorat J, Vedeler CA. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes. J Neurol. 2016 May;263(5):1001-7. [PMID: 27007485]
     
  • Haukanes BI, Hegvik TA, Eichler T, Haavik J, Vedeler CA. Paraneoplastic syndrome-associated neuronal antibodies in adult ADHD. J Neuroimmunol. 2015 Nov 15;288:87-91. [PMID: 26531699]
     
  • Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol (2014) 128:835–852. [PMID: 25341622]
     
  • Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A, Haukanes BI, Vedeler CA. CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS One. 2013 Jun 18;8(6). [PMID: 23823982]
     
  • Totland C, Ying M, Haugen M, Mazengia K, Storstein A, Aarseth J, Martinez A, Vedeler CA. Avidity of onconeural antibodies is of clinical relevance. Cancer Immunol Immunother. 2013 Aug;62(8):1393-6. [PMID: 23733227]
     
  • Tzoulis C, Vedeler C, Haugen M, Storstein A, Tran GT, Gjerde IO, Biermann M, Schwarzlmüller T, Bindoff LA. Progressive striatal necrosis is associated with anti-NMDAR antibodies. BMC Neurol. 2013, 31;13:55. [PMID: 23725534]
     
  • Olberg H, Haugen M, Storstein A, Vedeler CA. Neurological manifestations related to level of voltage-gated potassium channel antibodies. J Neurol Neurosurg Psychiatry. 2013, 84(8):941-3. [PMID: 23595945]
     
  • Giometto B, Vitaliani R, Lindeck-Pozza E, Grisold W, Vedeler CA. Treatment for paraneoplastic neuropathies. Cochrane Database Syst Rev. 2012 Dec 12;12. [PMID: 23235647]
     
  • Trier NH, Hansen PR, Vedeler CA, Somnier FE, Houen G. Identification of continuous epitopes of HuD antibodies related to paraneoplastic diseases/small cell lung cancer. J Neuroimmunol. 2012 Feb 29;243(1-2):25-33. [PMID: 22264992]
     
  • Raspotnig M, Vedeler CA, Storstein A. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance. Acta Neurol Scand Suppl 2011; 191: 83-8. [PMID: 21711262]
     
  • Vigliani MC, Honnorat J, Antoine JC, Vialiani R, Giometto B, Psimaras D, Franchino F, Rossi C, Graus F; PNS EuroNetwork. Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. J Neurol 2011; 258: 2058-68. [PMID: 21559939]
     
  • Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler CA, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler. 2011; 17: 1074-8. [PMID: 21511692]
     
  • Briani C, Vitaliani R, Grisold W, Honnorat J, Graus F, Antoine JC, Bertolini G, Giometto B; PNS Euronetwork. Spectrum of paraneoplastic disease associated with lymphoma. Neurology. 2011;76:705-10. [PMID: 21339498]
     
  • Totland C, Aarskog NK, Eichler TW, Haugen M, Haukanes BI, Vedeler CA. CDR2 antigen and Yo antibodies. Cancer Immunol Immunother 2011; 60:283-9. [PMID: 21080165]
     
  • Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJ. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011 Jan 18 [Epub ahead of print]. [PMID: 20880069
     
  • Storstein A, Monstad S, Haugen M et al. Onconeural antibodies: improved detection and clinical correlations. J Neuroimmunol. 2011;232:166-70. [PMID: 21093932]